GSK Cancer Vaccine Fails Again, Testing Continues

An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to identify a sub-group of patients on which it would work.   Thursday's news that the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in a late-stage study is a further blow to the high-risk, high-reward project after a similar setback in melanoma in September.   Unlike traditional...

© La Voix de l'Amérique - jeudi 20 mars 2014